TABLE 1.

Dosing and kinetics in the in vivo and in vitro models

Antibiotic	Dose (mg/kg of body weight) in vivo and route of administration	Peak level in serum in vivo (μg/ml)	Level in cages (μg/ml)		Level in in vitro culture compartments (μg/ml)		t1/2 in vitro (h)d
			Peaka	Troughb	Peakc	Troughb
Amikacin	20, i.m.e	46 (n = 3)	7.42 (n = 10)	2.72 (n = 10)	7.4	2.8	7.93
Levofloxacin	10, i.p.	5.22 (n = 3)	1.47 (n = 12)	0.27 (n = 12)	1.5	0.28	4.18
Rifampin	25, i.p.f	14.5 (n = 3)	6.32 (n = 12)	0.63 (n = 12)	6.3	0.66	2.45
Teicoplanin	6.6, i.p.	15 (n = 3)	14.1 (n = 12)	3.7 (n = 12)	14.1	3.7	4.18

^aPeak levels in the infected tissue cages were achieved with rifampin and teicoplanin after 4 h, with amikacin after 1 h, and with levofloxacin after 2 h. 

^bTrough levels in the infected tissue cages and culture compartments were achieved with all antibiotics after 12 h. 

^cPeak levels in the in vitro culture compartments were achieved with rifampin and teicoplanin after 4 hs of continuous infusion, with amikacin after 1 h of continuous infusion, and with levofloxacin after 2 h of continuous infusion (concentrations were estimated by measuring the dilution profile of a test substance). 

^dt_1/2, half-life. 

^ei.m., intramuscularly. 

^fi.p., intraperitoneally.